报价延迟最少15分钟:2026/04/15 16:27 EDT
盘后时段
|
||||
|
3.82 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.82
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.50/1.29
|
|
企业价值
154.24M
|
| 资产负债 |
|
每股账面净值
4.94
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.00M
|
|
每股收益
0.07
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901. |
